Log in

NASDAQ:MTNBMatinas Biopharma Stock Price, Forecast & News

+0.02 (+2.53 %)
(As of 08/5/2020 04:00 PM ET)
Today's Range
Now: $0.83
50-Day Range
MA: $0.80
52-Week Range
Now: $0.83
Volume1.67 million shs
Average Volume2.33 million shs
Market Capitalization$165.06 million
P/E RatioN/A
Dividend YieldN/A
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:MTNB
Phone908 443 1860



Sales & Book Value

Annual SalesN/A



Market Cap$165.06 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableNot Optionable
+0.02 (+2.53 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Matinas Biopharma (NASDAQ:MTNB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Matinas Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Matinas Biopharma

When is Matinas Biopharma's next earnings date?

Matinas Biopharma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Matinas Biopharma

How can I listen to Matinas Biopharma's earnings call?

Matinas Biopharma will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Matinas Biopharma's earnings last quarter?

Matinas Biopharma Holdings, Inc. (NASDAQ:MTNB) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03).
View Matinas Biopharma's earnings history

Has Matinas Biopharma been receiving favorable news coverage?

Media coverage about MTNB stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Matinas Biopharma earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Matinas Biopharma

Who are some of Matinas Biopharma's key competitors?

Who are Matinas Biopharma's key executives?

Matinas Biopharma's management team includes the following people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 46, Pay $644.79k)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 50, Pay $249.05k)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 53, Pay $380.62k)
  • Dr. James J. Ferguson, Chief Medical Officer (Age 67, Pay $461.46k)
  • Dr. Raphael J. Mannino, Chief Scientific Officer (Age 73)

What is Matinas Biopharma's stock symbol?

Matinas Biopharma trades on the NASDAQ under the ticker symbol "MTNB."

How do I buy shares of Matinas Biopharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Matinas Biopharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.83.

How big of a company is Matinas Biopharma?

Matinas Biopharma has a market capitalization of $165.06 million. Matinas Biopharma employs 15 workers across the globe.

What is Matinas Biopharma's official website?

The official website for Matinas Biopharma is www.matinasbiopharma.com.

How can I contact Matinas Biopharma?

The company can be reached via phone at 908 443 1860.

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.